Brief: microbiome diversity and autoimmune risk

A 2024 prospective cohort study has added longitudinal evidence to a question researchers have been circling for over a decade: does gut microbiome dysbiosis precede autoimmune disease, or merely accompany it? The answer, at least for rheumatoid arthritis, appears to be both - and the preclinical window may be years long.

What the study found

The study followed over 1,000 participants with elevated genetic risk for rheumatoid arthritis across a median follow-up of nine years. At baseline, stool microbiome composition was sequenced and alpha diversity (species richness within a sample) was calculated. Participants in the lowest tertile of microbiome diversity had a significantly higher rate of developing anti-CCP seropositivity - a preclinical marker of RA that typically appears years before joint symptoms - than those in the highest tertile.

The association held after controlling for genetics, diet, antibiotic use, and family history. The finding does not establish causation, but it extends earlier cross-sectional evidence into the preclinical window, suggesting that dysbiosis is not simply a consequence of immune activation but may be part of the causal chain.

Prevotella copri - the bacterial signal
Scher et al.'s 2013 eLife paper first identified Prevotella copri enrichment in new-onset RA patients compared to controls and healthy subjects. The 2024 longitudinal work found similar enrichment at baseline in participants who later developed anti-CCP positivity - before any clinical symptoms. Whether P. copri is a cause, a marker, or an opportunistic coloniser remains under active investigation.

The gut-immune axis

The intestinal microbiome plays a central role in educating and regulating immune tolerance. The balance between regulatory T cells (Tregs) - which suppress inappropriate immune activation - and pro-inflammatory Th17 cells is partly maintained by microbial metabolites, particularly short-chain fatty acids produced by butyrate-generating bacteria. Dysbiosis that depletes butyrate producers tips this balance toward autoimmunity.

Women carry roughly four times the autoimmune disease risk of men, for reasons that include hormonal effects on immune regulation and sex differences in gut microbiome composition. Estrogen modulates the microbiome and vice versa - a bidirectional relationship that may partially explain why autoimmune incidence peaks in women at reproductive ages and again post-menopause.

What this means practically

Microbiome testing does not currently diagnose autoimmune disease or predict individual outcomes with clinical precision. What it can provide is a characterisation of the inflammatory landscape: diversity index, butyrate-producer prevalence, Prevotella burden, calprotectin (intestinal inflammation marker), and secretory IgA (mucosal defense). Collectively these paint a picture of immune-gut axis health.

For women with a family history of rheumatoid arthritis, lupus, or other autoimmune conditions, gut health monitoring alongside conventional autoimmune markers (ANA, anti-CCP, complement) offers an earlier and broader view of immune trajectory than either alone.